# A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

> **NCT00399477** · PHASE4 · COMPLETED · sponsor: **Teva Neuroscience, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** rasagiline mesylate
- **DRUG:** Rasagiline mesylate plus Mirapex
- **DRUG:** Rasagiline mesylate with Levodopa
- **DRUG:** Rasagiline mesylate with Requip

## Key facts

- **NCT ID:** NCT00399477
- **Lead sponsor:** Teva Neuroscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399477, "A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00399477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*